Breaking News, Collaborations & Alliances

Fujifilm Inks Cell Therapy Deal with Novo Nordisk

Fujifilm Cellular Dynamics licenses its iPSC platform for the development of iPSC-derived cell therapies.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Fujifilm Cellular Dynamics, a global developer and manufacturer of human induced pluripotent stem cells (iPSC), has entered an agreement to grant Novo Nordisk a non-exclusive right to use its iPSC platform for the development and commercialization of iPSC-derived cell therapies with a focus on addressing serious chronic diseases. Novo Nordisk will have a non-exclusive license to use the iPSC cell lines for research and development purposes, and to utilize GMP-grade cell lines for clinical and...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters